written on 01.04.2014
Tags:
,

GSK ditches ovarian cancer plans for Votrient

TAGS: ,

GlaxoSmithKline said Monday that after reviewing data from a Phase III trial, it has withdrawn its application to the European Medicines Agency seeking to expand approval of Votrient to include women with advanced ovarian cancer.

Latest Report